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LETTERS TO THE EDITOR
Peripheral Skin Edema
as Unusual Toxicity in
Three Patients with
Advanced Non-small
Cell Lung Cancer
Treated with
Pemetrexed Alone
or in Combination
with Cisplatin
To the Editor:
Pemetrexed (P) represents one of
the most widely used drugs in the treat-
ment of patients with nonsquamous non-
small cell lung cancer with a favorable
toxicity profile. Rash, desquamation, and
pruritus are the most frequent cutaneous
toxicities.1 Recently, a series of 14 patients
with peripheral skin edema related to P ad-
ministration has been reported.2 The most
relevant aspects of this clinical picture were
fluid retention or cellulites, mainly localized
to the distal lower extremities ranging from
ankle swelling to pitting edema with overly-
ing skin erythema.
CASE REPORTS
Retrospectively, we identified three
cases showing similar signs and symptoms
to those described by D’Angelo et al.2 of the
120 patients with advanced non-small cell
lung cancer treated with P in the last 5 years
at our institution. Two patients (A and B)
received P in combination with cisplatin as
first-line treatment and one patient (C) was
given P as second-line treatment.
Patient A, a 59-year-old man devel-
oped skin edema to bilateral lower ex-
tremities after the fourth cycle of therapy,
which initially was treated with topical
steroids. There was significant worsening
of the condition after the fifth cycle. Der-
matologist diagnosed erysipelas and
started antibiotic therapy with macrolides,
in combination with systemic steroids, ob-
taining a slight improvement. The sixth
cycle, administered with a 25% dose re-
duction of P, was associated with a flare of
the edema (Figure 1). P was discontinued
with a complete disappearance of the
edema within 30 days.
Patient B, a 65-year-old woman
showed intense unilateral dermatologic
toxicity of the lower extremity after the
second cycle of chemotherapy. Systemic
steroid therapy led to improvement of lo-
cal signs and symptoms. The patient pro-
gressed after the fourth cycle, and she then
received second-line therapy with com-
plete resolution of P-related toxicity
within 20 days.
Patient C, a 66-year-old man devel-
oped bilateral lower leg edema and ery-
thema after the third cycle of P. Treatment
with diuretics was ineffective, and a 25%
dose reduction of P with the fourth cycle
was not associated with improvement.
Subsequently, systemic steroid therapy
was started with a further dose reduction
of P, leading to disappearance of skin
findings. In all patients, the vascular
echodoppler study was negative for phle-
bitis; no patient underwent biopsy.
DISCUSSION
During the clinical development of
P, skin rash was described, although little
is published about its mechanism. Lopes
et al.3 performed cutaneous biopsies and
described an urticarial vasculitis (UV);
findings similar to those were observed in
rheumatologic diseases or with drugs such
as diltiazem and procarbazine. The au-
thors considered UV as one of the possible
manifestations of P-related rash. Indeed, this
UV is in contrast to common urticaria,
which resolves in minutes to hours and may
migrate. As described herein, the lesions
may be painful or pruritic and resolve with
purpura or hyperpigmentation. Treatment of
choice seems to be dose reduction of P,
combined with systemic steroids. Treatment
discontinuation should be considered only in
nonresponsive patients.
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FIGURE 1. Clinical presentation of the patient’s lower extremity edema after sixth
cycle of pemetrexed.
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